Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mitral Stenosis I: Introduction

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...

Mitral Valve Prolapse III: Nursing Management

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...

Peripheral Artery Disease IV: Nursing Management

Peripheral Artery Disease IV: Nursing Management

The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...

Mitral Stenosis IV: Nursing Management

Mitral Stenosis IV: Nursing Management

A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety of Ready-to-Eat Green Leafy Salads: Growth Potential of <i>Listeria monocytogenes</i> During Shelf Life.

Foods (Basel, Switzerland)·2026

Same author

Subtype-Specific Risk of Non-Melanoma Skin Cancers in MPN Patients: An Expanded Analysis of the MPN-K Case-Control Database.

American journal of hematology·2026

Same author

Changes in neutrophil-to-lymphocyte ratio in patients with polycythemia vera treated with ruxolitinib reflect <i>JAK2</i> variant allele frequency.

Haematologica·2026

Same author

Polycythemia vera.

Mayo Clinic proceedings·2026

Same author

Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Blood·2026

Same author

From essential thrombocythemia to polycythemia vera (ET-2-PV): rationale and design of a multicenter ELN study.

Annals of hematology·2026

Search research articles

Related Experiment Video

Updated: May 7, 2026

A Patient-Derived Xenograft Model for Venous Malformation

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

Are MPNs vascular diseases?

Guido Finazzi¹, Valerio De Stefano, Tiziano Barbui

¹Division of Hematology, Ospedale Papa Giovanni XXIII, Piazza OMS, 1, 24127, Bergamo, BG, Italy, gfinazzi@hpg23.it.

Current Hematologic Malignancy Reports

|September 17, 2013

Summary

This summary is machine-generated.

Myeloproliferative neoplasms (MPNs) like polycythemia vera (PV) and essential thrombocythemia (ET) significantly increase thrombosis risk. Management involves anticoagulants, aspirin, phlebotomy, and myelosuppressive agents to reduce vascular complications.

More Related Videos

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Published on: June 23, 2014

Related Experiment Videos

Last Updated: May 7, 2026

A Patient-Derived Xenograft Model for Venous Malformation

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Published on: June 23, 2014

Area of Science:

Hematology
Oncology
Vascular Medicine

Background:

Chronic myeloproliferative neoplasms (MPNs), including polycythemia vera (PV) and essential thrombocythemia (ET), are characterized by a high risk of arterial and venous thrombosis.
Thrombosis in MPNs shares clinical and pathogenetic features with other vascular diseases, including inherited thrombophilias and atherosclerosis.

Purpose of the Study:

To review the clinical aspects, pathogenesis, and management of thrombosis in MPNs.
To highlight the commonalities between MPN-associated thrombosis and other vascular pathologies.
To discuss current therapeutic strategies for reducing thrombosis in MPNs.

Main Methods:

Literature review and synthesis of existing research on MPN-associated thrombosis.
Comparison of MPN thrombosis with inherited thrombophilias, atherosclerosis, and thrombosis in solid cancers.
Analysis of therapeutic options including anticoagulants, aspirin, phlebotomy, and myelosuppressive agents.

Main Results:

MPN-associated thrombosis involves atypical venous sites and acquired resistance to activated protein C, linking it to inherited thrombophilia.
Leukocyte and inflammation roles, along with high mortality from arterial occlusions, connect MPNs to atherosclerosis.
Aspirin has proven efficacy in reducing thrombosis and mortality in PV.
Virchow's triad (impaired blood cells, endothelium, blood flow) is relevant to both MPNs and thrombosis in cancer.

Conclusions:

Anticoagulants are primary for managing thrombotic complications in MPNs.
Aspirin is effective for reducing thrombosis and mortality in PV.
Phlebotomy and myelosuppressive agents are key therapies for correcting underlying abnormalities and preventing thrombosis in MPNs.